

The Canadian Journal of Neurological Sciences

Le Journal Canadien des Sciences Neurologiques



- Pathophysiology of Basal Ganglia Disorders 177
- Pathogenesis of Mesial Temporal Sclerosis 184
- NMR of CSF in Multiple Sclerosis 194
- Encephalopathy after Lymphoblastic Leukemia 237
- Complete Table of Contents i


XXIXth Canadian Congress of
Neurological Sciences
June 27 - 30, 1994
St. John's, Newfoundland

The Official Journal of

The Canadian Neurological Society
The Canadian Neurosurgical Society
The Canadian Society of Clinical Neurophysiologists
The Canadian Association of Child Neurology

Volume 20, No. 3

August 1993



To a parkinsonian patient, a little help means a lot.

Adding Parlodel to levodopa can improve symptom control. Because you want to help your patient get more out of life's little pleasures.

Add

PARLODEL[®] 
(bromocriptine mesylate)

Because quality of life
is the issue.

 **SANDOZ**

Sandoz Canada Inc.
P.O. Box 385
Dorval, Quebec
H9R 4P5



For brief prescribing information see page x



Table of Contents

ARTICLES

| | |
|---|-----|
| Physiology of Basal Ganglia Disorders: An Overview – Silversides Lecture <i>Mark Hallett</i> | 177 |
| Pathogenesis of Mesial Temporal Sclerosis – Review Article <i>C. Elizabeth Pringle, Warren T. Blume, David G. Munoz and L. Stan Leung</i> | 184 |
| Nuclear Magnetic Resonance Study of Cerebrospinal Fluid From Patients With Multiple Sclerosis <i>Joanna Lynch, James Peeling, Anthony Auty and Garnette R. Sutherland</i> | 194 |
| Severe Permanent Encephalopathy in Acute Lymphoblastic Leukemia <i>Bernard L. Maria, Maureen Dennis and Marc Obonsawin</i> | 199 |
| Serum and Lipoprotein Fatty Acid Profile in Hereditary Ataxias <i>L. Iorio, G. De Michele, A. Filla, L. Di Martino, A. Postiglione, L. Patti and G. Campanella</i> | 206 |
| The Usefulness of CT Scanning in Diagnosing Dementia of the Alzheimer Type <i>J. Willmer, A. Carruthers, D.A. Guzman, B. Collins, J. Pogue and D.T. Stuss</i> | 210 |
| The Use of Antiepileptic Drug Levels in Children: A Survey of Canadian Pediatric Neurologists <i>J.M. Dooley, P.R. Camfield, C.S. Camfield, K.E. Gordon and A.D. Fraser</i> | 217 |
| Contact Thermography in the Diagnosis of Childhood Migraine <i>Jorg R. Wolstein, Martin H. Reed, Shashi S. Seshia, P. Kubrakovich, B. Lindsey and A. Samuel</i> | 222 |
| Inflammatory Myopathy and Walker-Warburg Syndrome: Etiologic Implications <i>Michael I. Shevell, Bernard Rosenblatt and Kenneth Silver</i> | 227 |
| Dural Cavernous Hemangioma: An Under-recognized Lesion Mimicking Meningioma <i>James R. Perry, William S. Tucker, Mario Chui and Juan M. Bilbao</i> | 230 |
| Failure to Recognize Status Epilepticus in a Paralyzed Patient <i>R.I. Munn and K. Farrell</i> | 234 |
| Tremorgenic Encephalopathy: A Role of Mycotoxins in the Production of CNS Disease in Humans? <i>K. E. Gordon, R.E. Masotti and W.R. Waddell</i> | 237 |
| Syrinx Extending from Conus Medullaris to Basal Ganglia: A Clinical, Radiological and Pathological Correlation <i>Marc R. Del Bigio, John H.N. Deck and J. Kerry MacDonald</i> | 240 |

HYPOTHESIS

| | |
|--|-----|
| Concerning Mind <i>C. Miller Fisher</i> | 247 |
|--|-----|

HISTORICAL NEUROLOGY AND NEUROSURGERY

| | |
|---|-----|
| William John Horsey, M.D., F.R.C.S.C – Neurosurgeon to St. Michael's Hospital, Toronto <i>J. Max Findlay and William S. Tucker</i> | 254 |
|---|-----|

| | |
|--------------------|-----|
| BOOK REVIEWS | 256 |
|--------------------|-----|

| | |
|-------------------------------|-----|
| NOTES AND ANNOUNCEMENTS | 260 |
|-------------------------------|-----|

| | |
|--------------------------|-----|
| CALENDAR OF EVENTS | 261 |
|--------------------------|-----|

| | |
|-------------------------------|----|
| INSTRUCTIONS TO AUTHORS | iv |
|-------------------------------|----|

| | |
|-------------------------|-------|
| ADVERTISERS INDEX | xviii |
|-------------------------|-------|



Editor/Rédacteur en chef

James A. Sharpe *Toronto, ON*

Associate Editors/Rédacteurs associés

Laurence E. Becker *Toronto, ON*

John P. Girvin *London, ON*

Terry W. Picton *Ottawa, ON*

Past Editors

Robert G. Lee *Calgary, AB*

Robert T. Ross (founding editor)

Winnipeg, MB

Editorial Board/Conseil Scientifique

Warren T. Blume *London, ON*

Jean-Pierre Bouchard *Québec, PQ*

Donald B. Calne *Vancouver, BC*

Peter R. Camfield *Halifax, NS*

Pierre Duquette *Montréal, PQ*

Peter J. Dyck *Rochester, MN, USA*

George C. Ebers *London, ON*

Serge Gauthier *Montréal, PQ*

Julian T. Hoff *Ann Arbor, MI, USA*

Peter Humphreys *Ottawa, ON*

George Karpati *Montréal, PQ*

Richard Leblanc *Montréal, PQ*

Patrick L. McGeer *Vancouver, BC*

William Pryse-Phillips *St. Johns, NF*

Ali H. Rajput *Saskatoon, SK*

Richard J. Riopelle *Kingston, ON*

Richard Stein *Edmonton, AB*

John Stewart *Montréal, PQ*

Garnette R. Sutherland *Calgary, AB*

Charles H. Tator *Toronto, ON*

Book Review Editor/

Rédacteur de critiques de livres

Mary Anne Lee *Calgary, AB*

News Editor/Rédacteur (nouvelles)

John W. Norris *Toronto, ON*

Managing Editor/Administratrice adjointe

Sally A. Gregg *Calgary, AB*

Publications Committee/Comité de Rédaction

Frances Booth *Winnipeg, MB*

Donald Brunet *Kingston, ON*

Gary Ferguson *London, ON*

William Pryse-Phillips *St. John's, NF*

The Official Journal of:/La Revue Officielle de:

**The Canadian Neurological Society
La Société Canadienne de Neurologie**

President/Président — C.W. McCormick

Secretary-Treasurer/Secrétaire-Trésorier — O. Suchowersky

**The Canadian Neurosurgical Society
La Société Canadienne de Neurochirurgie**

President/Président — H.J. Hoffman

Secretary-Treasurer/Secrétaire-Trésorier — Renn Holness

**The Canadian Society of Clinical Neurophysiologists
La Société Canadienne de Neurophysiologie Clinique**

President/Président — Michael Jones

Secretary-Treasurer/Secrétaire-Trésorier — Bryan Young

**The Canadian Association of Child Neurology
L'Association Canadienne de Neurologie Pédiatrique**

President/Président — Shashi Seshia

Secretary-Treasurer/Secrétaire-Trésorier — William Logan

The permanent secretariat for the 4 societies and the Canadian Congress of Neurological Sciences is at/
Le secrétariat des 4 associations et du Congrès Canadien des Sciences Neurologiques est situé en permanence à:
810, 906 - 12 Avenue S.W., Calgary, AB Canada T2R 1K7

The Canadian Journal of Neurological Sciences is published quarterly. The annual subscription rate is \$60 for members; \$70 for non-members in Canada; \$80 for USA and elsewhere. Residents, Interns, Pre- and Post-Doctoral Students \$30 per annum (members); \$40 per annum (non-members). Single copies \$18 each plus postage and handling. All manuscripts and communications should be sent to: Canadian Journal of Neurological Sciences, P.O. Box 4220, Station C, Calgary, AB Canada T2T 5N1. Courier to: 8th Floor, 906 - 12th Avenue S.W., Calgary, AB Canada T2R 1K7. Telephone (403) 229-9575.
COPYRIGHT© 1993 by THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. No part of this journal may be reproduced in any form without the prior permission of The Canadian Journal of Neurological Sciences. Mailed under Publications Mail registration number 3307. Postage paid at Calgary, Alberta. This journal is indexed by *Index Medicus*, *Excerpta Medica* and *Current Contents — Clinical Practice and Life Sciences*.

Le Journal Canadien des Sciences Neurologiques est publié trimestriellement. L'abonnement annuel est de 60 \$ pour les membres; 70 \$ pour les non-membres au Canada; 80 \$ pour les Etats Unis et ailleurs. Internes, résidents, fellows pré et post doctoral: 30 \$ par année (membres); 40 \$ par année (non-membres). Copie simple: 18 \$ plus affranchissement et manutention. Toutes les communications et les manuscrits doivent être adressés à Journal Canadien des Sciences Neurologiques, P.O. Box 4220, Station C, Calgary, AB Canada T2T 5N1. Par courrier: 8th Floor, 906 - 12th Avenue S.W., Calgary, AB Canada T2R 1K7. Téléphone (403) 229-9575.
DROITS D'AUTEUR© 1993: THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. Aucune partie de ce Journal ne peut être reproduite, sous quelque forme que ce soit, sans la l'autorisation du Journal Canadien des Sciences Neurologiques. Posté sous permis de poste-publications no 3307. Port payé à Calgary, Alberta. Le Journal est cité et indexé dans *Index Medicus*, *Excerpta Medica* et *Current Contents — Clinical Practice et Life Sciences*.

Advertising representative/Représentant de publicité Sally Gregg, Canadian Journal of Neurological Sciences
810, 906 - 12 Ave. S.W., Calgary, AB Canada T2R 1K7 — (403)-229-9575

Printer/Imprimeur McArA Printing Limited, 105, 2507 - 12th Street N.E., Calgary, Alberta T2E 7L5

ISSN 0317 - 1671

Une approche bien orchestrée



Une thérapie rationnelle par Frisium représente une approche bien orchestrée pour maîtriser complètement les crises chez les patients épileptiques de tout âge, quel que soit le type de crise. Avec Frisium, les effets adverses sont généralement bénins et passagers¹. Les interactions médicamenteuses cliniquement significatives sont rares et l'altération de la vigilance est moins prononcée avec Frisium qu'avec les autres benzodiazépines. Aidez les patients à vivre en harmonie avec leur milieu.*

Ajoutez
Frisium[®] (clobazam)
Pour maîtriser les crises.

CCPP FRI 2698/9053F

* Veuillez consulter la rubrique Précautions dans la monographie.

 , Hoechst et ®, Marques déposées Hoechst AG, Allemagne

Hoechst Canada Inc., Montréal H4R 2E8

Hoechst 

INFORMATION FOR AUTHORS

The Canadian Journal of Neurological Sciences publishes original articles in neurology, neurosurgery and basic neurosciences. Manuscripts are considered for publication with the understanding that they, or the essence of their content, have not been published elsewhere except in abstract form and are not under simultaneous consideration by another journal. Manuscripts should be submitted to:

James A. Sharpe
Editor
Canadian Journal of Neurological Sciences
P.O. Box 4220, Station "C"
Calgary, Alberta
T2T 5N1, Canada

Manuscript Preparation

Submit five high quality copies of the manuscript. Papers will be accepted in English or French. All papers should be accompanied by an abstract of 150 words or less on a separate page, preferably in both languages, although the Journal will provide the translation if required. Submit two original sets and three copies of illustrations. All manuscripts must be double spaced throughout including references and legends for illustrations. Margins of at least 25mm should be left on all sides.

For detailed instructions regarding style and layout, authors should refer to "Uniform requirements for manuscripts submitted to biomedical journals". Copies of this document may be obtained by writing to the Journal office, but the main points are summarized here. Articles should be submitted under conventional headings of "introduction", "methods and materials", "results", "discussion", but other headings and subheadings will be considered if more suitable for a particular manuscript.

A title page should identify the title of the article, authors, name of institution(s) from which the work originated and the address, telephone and fax numbers of the corresponding author. Pages of text should be numbered consecutively. Acknowledgements, including recognition of financial support should be typed on a separate page at the end of the text.

The SI system (système international d'unités) should be used in reporting all laboratory data, even if originally reported in another system. Temperatures are reported in degrees celsius. English language text may use either British or American spelling, but should be consistent throughout.

After the paper has been reviewed, the corresponding author will be requested to submit four printouts of the revised manuscript and a computer floppy disk (3 1/2" or 5 1/4" size) containing the article. Identify clearly on the disk: system - i.e.: MS dos or Macintosh; format - i.e.: saved in ASCII format; software program and version; first author's name printed on the disk.

Review Articles on selected topics are also published by the Journal. They are usually invited, but unsolicited reviews will be considered. It is recommended that authors intending to submit review articles contact the Editor in advance.

Letters to the Editor: Letters concerning matters arising in recent articles are welcome. Letters should be limited to two double-spaced pages and may include one illustration and a maximum of four references.

References

Number references in the order of their citation in the text. Those cited only in tables or in legends for illustrations are numbered according to the sequence established by the first identification in the text of a particular table or illustration. Titles of journals should be abbreviated according to the style used in Index Medicus. References should include the names of up to five authors; if there are more, cite the first three, then "et al.". Provide the full title, year of publication, volume number and inclusive pagination for journal articles. For any reference cited as "in press", five copies of the article must accompany the author's manuscript. Do not reference unpublished or "submitted" papers; these can be mentioned in the body of the text and authors must provide five copies of "submitted" manuscripts. Avoid "personal communications" and, if necessary, include them in the body of the text, not among the references. Reference citations should not include unpublished presentations or other non-accessible material. Books or chapter references should also include the place of publication and the name of the publisher. Examples of correct forms of reference follow:

Journals

Yang JF, Fung M, Edamura R, et al. H-Reflex modulation during walking in spastic paretic subjects. *Can J Neurol Sci* 1991; 18: 443-452.

Chapter in a book

McGeer PL, McGeer EG, Amino acid neurotransmitters. In: Siegel GJ, Albers RW, Agranoff BW, Katzman R, eds. *Basic Neurochemistry*. Boston: Little, Brown & Co., 1981: 233-254.


Illustrations

Submit five original sets of illustrations. We will not return illustrations; therefore, authors should keep negatives for all photographs. Submit high quality glossy black and white photographs preferably 127 x 173 mm (5" x 7"). Original art work and radiographs should not be submitted. The additional cost of coloured illustration must be borne by the authors; quotations are available upon request from the Journal office. Identify each figure with a label at the back indicating top, figure number and first author. Letters and arrows applied to the figures to identify particular findings should be professional appliques suitable for publication. Photomicrographs should include a calibration bar with a scale indicated on the figure or in the legend. Legends for illustrations should be typed on a separate page from the illustrations.

Tables

Type tables double-spaced on pages separate from the text. Provide a table number and title for each. Particular care should be taken in the preparation of tables to ensure that the data are presented clearly and concisely. Each column should have a short or abbreviated heading. Place explanatory matter in footnotes, not in the heading. Do not submit tables as photographs.

It's about time...



In the 50s, GABA (γ -aminobutyric acid) was identified as an inhibitory neurotransmitter.


In the 60s, GABA-transaminase (GABA-T) was pinpointed as an enzyme involved in GABA breakdown.

Research led to the suspicion that GABA activity impairment may play a role in epilepsy, and that if GABA levels were increased, seizures might decrease. However, the first GABA-related medication was only introduced in the early 70s in North America.


Its mode of action and effect on GABA are unknown.

Specific GABA-T inhibitors have been developed and tested on animals and humans. They reduce GABA-T activity and increase the pre-synaptic GABA pool.

Specific GABA-T inhibition – an important step toward better seizure control.



Pinpointing GABA-T for better seizure control



MARION MERRELL DOW

CANADA

(v)



*There's only one thing
your TIA patients want from a
stroke prevention therapy.*

Tomorrow.

What patients at risk want most is the reassurance everything possible is being done to prevent another event.

By making Ticlid a part of your patients' treatment, you can give them that reassurance.

Because for non-cardiogenic thromboembolic stroke – the most common form of the disease¹ – there is no therapy proven more effective than Ticlid.

In two landmark studies, Ticlid has been shown to significantly reduce the risk of both initial and recurrent stroke.^{2,3}

During the critical first year after a TIA, Ticlid reduced the incidence of stroke by nearly half relative to ASA. And its superiority was maintained over a 5 year term, in women as well as men.^{2,4}

Ticlid also performed significantly better than placebo in

recurrent stroke, and remains the only therapy indicated for the prevention of initial and recurrent stroke in both men and women.^{3,5}

With Ticlid, side effects have been shown to be manageable, transient and to occur early in therapy, with most common side effects being relieved by a temporary dose reduction.^{2,6}

In clinical trials, there was a 2.4% incidence of neutropenia (0.8% severe). Upon immediate discontinuation of therapy, the neutrophil count usually returned to normal within one to three weeks.^{2,3}

To manage the condition requires regular WBC monitoring every two weeks for the first three months of therapy.⁶

Ticlid. After you tell your patients about the risk of stroke, tell them about Ticlid.

And let them get on with their lives.

Ticlid Information Hotline
1-800-263-8918
Dosage: 250 mg BID with meals

Ticlid[®]

ticlopidine hydrochloride 250 mg tablets

*Nothing protects patients
from stroke more effectively.*



Ticlid[®]

TICLID (ticlopidine hydrochloride) 250 mg Tablets

THERAPEUTIC CLASSIFICATION Inhibitor of Platelet Function

ACTION Ticlid (ticlopidine hydrochloride) is an inhibitor of platelet aggregation. It causes a time and dose-dependent inhibition of platelet aggregation and release of platelet factors, as well as a prolongation of bleeding time. The drug has no significant *in-vitro* activity.

The exact mechanism of action is not fully characterized, but does not involve inhibition of the prostacyclin/thromboxane pathways or platelet cAMP.

Ticlid interferes with platelet membrane function by inhibiting ADP-induced platelet-fibrinogen binding and subsequent platelet-platelet interactions. The effect of Ticlid on platelet function is irreversible.

Template bleeding time is usually prolonged by two to five-fold of baseline values with the therapeutic dose of Ticlid.

Upon discontinuation of Ticlid dosing, bleeding time and other platelet function tests return to normal within one week in the majority of patients.

The correlation between ticlopidine hydrochloride plasma levels and activity is still under investigation. Much of the following data was obtained from older patients corresponding to the age of patients participating in clinical trials (mean age: 63 years).

After oral administration of the therapeutic dose of Ticlid, rapid absorption occurs, with peak plasma levels occurring at approximately 2 hours after dosing. Absorption is at least 80% complete. Administration of Ticlid after meals results in an increased (20%) level of ticlopidine hydrochloride in plasma.

Steady state plasma levels of ticlopidine hydrochloride in plasma are obtained after approximately 14 days of dosing at 250 mg BID. The terminal elimination half-life is 4-5 days. However, inhibition of platelet aggregation is not correlated with plasma drug levels.

Ticlopidine hydrochloride binds reversibly (98%) to plasma proteins, mainly to serum albumin and lipoproteins in a non-saturable manner.

Ticlopidine hydrochloride is metabolized extensively by the liver; no intact ticlopidine hydrochloride is detected in the urine. Unmetabolized ticlopidine hydrochloride is a minor component in plasma after a single dose, but at steady state, ticlopidine hydrochloride is the major component.

Impaired hepatic function resulted in higher than normal plasma levels of unchanged ticlopidine hydrochloride after single doses or after multiple doses.

Inhibition of platelet aggregation is detected within 2 days of administration with 250 mg BID. Maximum platelet aggregation inhibition is achieved 8 to 11 days following dosing with 250 mg BID.

INDICATIONS AND CLINICAL USE Ticlid (ticlopidine hydrochloride) tablets are indicated for reduction of the risk of first or recurrent stroke for patients who have experienced at least one of the following events: Complete Thromboembolic Stroke, Minor Stroke, Reversible Ischemic Neurological Deficit (RIND), or Transient Ischemic Attack (TIA) including Transient Monocular Blindness (TMB).

CONTRAINDICATIONS Ticlid (ticlopidine hydrochloride) is contraindicated in the following conditions: 1. Known hypersensitivity to drug or its excipients. 2. Presence of haematopoietic disorders (such as neutropenia and/or thrombocytopenia). 3. Presence of haemostatic disorder. 4. Conditions associated with active bleeding, such as bleeding peptic ulcer or intracranial bleeding. 5. Severe liver dysfunction.

WARNINGS The following warnings were developed from clinical trial experience with over 2000 patients with cerebrovascular disease who were treated with ticlopidine for as long as 5.8 years.

Neutropenia and Thrombocytopenia: About 2.4% of ticlopidine-treated patients in clinical trials developed neutropenia (defined as an absolute neutrophil count (ANC) below 1.2×10^9 cells/L). The incidence of severe neutropenia (ANC < 0.45×10^9 cells/L) was 0.8%. Severe neutropenia occurs during the first 3-12 weeks of therapy, and may develop quickly over a few days. The bone marrow shows a reduction in myeloid precursors. The condition is reversible, and recovery usually occurs within 1-3 weeks after discontinuation of the drug.

In clinical trials, thrombocytopenia (defined as a platelet count of $< 0.8 \times 10^{11}$ cells/L) has been observed in 0.4% of ticlopidine patients. The incidence of thrombocytopenia in patients on ASA or placebo was 0.3% or 0.4% respectively. The thrombocytopenia may occur as an isolated finding or in combination with neutropenia. Thrombocytopenia occurs during the first 3-12 weeks of therapy, and recovery usually occurs after drug discontinuation.

All patients should have a white blood cell count with a differential count and platelet count performed every 2 weeks during the first 3 months of therapy. The incidence of neutropenia or thrombocytopenia after three months of therapy is not appreciably higher than the background levels observed in control groups, and continued periodic monitoring is not warranted. However, for the duration of ticlopidine therapy, any signs or symptoms suggestive of neutropenia or thrombocytopenia should be promptly investigated with complete blood counts and platelet counts.

Hemorrhagic Complications: Prolongation of bleeding time occurs in subjects treated with Ticlid. Purpura and a few cases of more serious hemorrhagic events such as hematemesis, melena, hemorthorax and intracranial bleeding have been reported. Patients must be instructed to watch for signs of bleeding disorders and to report any abnormality to their physician immediately. Ticlid therapy has to be stopped by the patient if a physician is not immediately available for consultation.

Anticoagulant Drugs: Should be avoided as tolerance and safety of simultaneous administration with Ticlid has not been established.

Hepatic Abnormalities: Most patients receiving ticlopidine hydrochloride showed some increase of their alkaline phosphatase values above their baseline and in one-third the increase exceeded the upper reference range. In 6% the value was greater than twice the upper reference range. These increases in alkaline phosphatase were nonprogressive and asymptomatic. In clinical trials, two cases (0.1%) of cholestatic jaundice accompanied by elevated transaminases alkaline phosphatase, and bilirubin levels above $43 \mu\text{mol/L}$ have been observed. Both patients recovered promptly upon drug discontinuation.

Pregnancy: The safety of Ticlid in pregnancy has not been established. It should not be used in pregnant patients.

Pediatric Use: Safety in children has not been studied. Do not use in pediatric patients.

PRECAUTIONS

Clinical Monitoring: All patients have to be carefully monitored for clinical signs and symptoms of adverse drug reactions (see ADVERSE REACTIONS). The signs and symptoms possibly related to neutropenia (fever, chills, sore throat, ulcerations in oral cavity), thrombocytopenia and abnormal hemostasis (prolonged or unusual bleeding, bruising, purpura, dark stool), jaundice (including dark urine, light coloured stool) and allergic reactions should be explained to the patients who should be advised to stop medication and consult their physician immediately if any of these occur.

Laboratory Monitoring: All patients should have a WBC count with differential and platelet count performed every 2 weeks during the first 3 months of therapy. Thereafter, the WBC counts need only be repeated for symptoms or signs suggestive of neutropenia. Liver function tests should be conducted during therapy with Ticlid (ticlopidine hydrochloride) in response to signs and symptoms suggestive of hepatic dysfunction.

Elective Surgery: Ticlid should be discontinued 10 to 14 days prior to elective surgery or dental extraction and bleeding time and thrombocyte count performed before the procedure if clinically indicated.

Emergency Surgery: Prolonged bleeding during surgery may be a problem in ticlopidine-treated patients. Transfusions of fresh platelets would be expected to improve haemostasis in such patients, but there are no data from clinical trials to confirm this expectation. There are data from clinical pharmacology trials that indicate treatment with glucocorticosteroids can normalize bleeding time in ticlopidine treated subjects, but there is no experience with ticlopidine-treated surgical patients to show that such treatment improves haemostasis.

Selection of Patients: Ticlid should be used only for the established indications (see INDICATIONS) and should not be given to patients with haematopoietic disorders, haemostatic disorders, patients suffering from conditions associated with active bleeding (see CONTRAINDICATIONS) and patients anticipating elective surgery. In clinical trials elderly patients tolerated the drug well, but safety in children and pregnant women has not been established.

Specific Precautions: Liver: Ticlid is contraindicated in patients with severe liver dysfunction or cholestatic jaundice. Mild increase of Alkaline Phosphatase may be seen for the duration of the treatment and is inconsequential in the majority of patients (see WARNINGS and CONTRAINDICATIONS).

Kidneys: Ticlid has been well tolerated in patients with moderately decreased renal function. In severe renal disease, caution and close monitoring are recommended.

Gastrointestinal System: Conditions associated with active bleeding, such as bleeding ulcers, constitute contraindication for Ticlid. Clinical judgement and monitoring of stool for occult blood are required for patients

with a history of ulcerative lesions. Trauma: Ticlid should be discontinued temporarily until the danger of abnormal bleeding is eliminated. A single fatal case of intracranial bleeding following head trauma has been reported. The extent to which Ticlid may have contributed to the severity of the bleeding is unknown.

Drug Interactions: The following table outlines the agents which have been concomitantly administered with ticlopidine hydrochloride and the observed interaction if any:

| AGENTS | OBSERVED INTERACTION |
|---|--|
| Acetylsalicylic acid (ASA) | Potentiation of ASA's effect on collagen-induced platelet aggregation (see WARNINGS). |
| Antipyrine and products metabolized by hepatic microsomal enzymes | 30% increase in t _{1/2} of antipyrine. Dose of products metabolized by hepatic microsomal enzymes to be adjusted when starting or stopping concomitant therapy with ticlopidine hydrochloride. |
| Theophylline | t _{1/2} of theophylline increased from 8.6 to 12.2 hr along with a comparable reduction in its total plasma clearance. |
| Digoxin | Approximately 15% reduction in digoxin plasma levels, (little or no change in digoxin's efficacy expected). |
| Cimetidine | Chronic administration of cimetidine induced a 50% reduction in clearance of a single dose of ticlopidine hydrochloride. 20% decrease in ticlopidine plasma level when administered after antacids. |
| Antacids | No interaction reported. |
| Phenobarbital | No interaction reported. |

Other Concomitant Therapy: Although specific interaction studies were not performed, in clinical studies, TICLID was used concomitantly with beta blockers, calcium channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (however see WARNINGS) without evidence of clinically significant adverse interactions.

ADVERSE REACTIONS Most adverse effects are mild, transient and occur early in the course of treatment. In controlled clinical trials of 1 to 5 years duration, discontinuation of Ticlid (ticlopidine hydrochloride) due to one or more adverse effects was required in 20.9% of patients. In these same trials, ASA and placebo led to discontinuation in 14.5% and 6.7% of patients respectively. The incidence rates of adverse reactions listed in the following table were derived from multicenter, controlled clinical trials comparing ticlopidine HCl, placebo, and ASA over study periods of up to 5 years. The rates are based on adverse reactions considered probably drug-related by the investigator. Adverse experiences occurring in greater than one percent of patients treated with Ticlid in controlled clinical trials are shown in the Table below.

PERCENT OF PATIENTS IN CONTROLLED STUDIES

| Event | Ticlid | ASA | Placebo | | Ticlid | ASA | Placebo |
|------------|------------|-----------|-----------|-------------|-----------|-----------|-----------|
| | (n=2048) | (n=1527) | (n=536) | | (n=2048) | (n=1527) | (n=536) |
| | Incidence | Incidence | Incidence | | Incidence | Incidence | Incidence |
| Diarrhea | 12.5(6.3)* | 5.2(1.8) | 4.5(1.7) | Nausea | 7.0(2.6) | 6.2(1.9) | 1.7(0.9) |
| Dyspepsia | 7.0(1.1) | 9.0(2.0) | 0.9(0.2) | Rash | 5.1(3.4) | 1.5(0.8) | 0.6(0.9) |
| GI Pain | 3.7(1.9) | 5.6(2.7) | 1.3(0.4) | Neutropenia | 2.4(1.3) | 0.8(0.1) | 1.4(0.4) |
| Purpura | 2.2(0.2) | 1.6(0.1) | 0.0(0.0) | Vomiting | 1.9(1.4) | 1.4(0.9) | 0.9(0.4) |
| Flatulence | 1.5(0.1) | 1.4(0.3) | 0.0(0.0) | Pruritus | 1.3(0.8) | 0.3(0.1) | 0.0(0.0) |
| Dizziness | 1.1(0.4) | 0.5(0.4) | 0.0(0.0) | Anorexia | 1.0(0.4) | 0.5(0.4) | 0.0(0.0) |

* Percent of patients (in parentheses) discontinuing clinical trials due to event
The incidence of thrombocytopenia in these controlled studies was 0.4% in the Ticlid and placebo groups of patients and 0.3% in the ASA patient population.

The following rare events have been reported and their relationship to Ticlid is uncertain. Pancytopenia, hemolytic anemia with reticulocytosis, thrombocytopenic thrombotic purpura, jaundice, allergic pneumonitis, systemic lupus (positive ANA), peripheral neuropathy, vasculitis, serum sickness, arthropathy, hepatitis, nephrotic syndrome, myositis, and hyponatremia.

Gastrointestinal: Ticlid therapy has been associated with a variety of gastrointestinal complaints including diarrhea and nausea. The majority of cases are mild and transient in nature and occur within 3 months of initiation of therapy. Typically, events are resolved within 1-2 weeks without discontinuation of therapy. If the effect is severe or persistent, therapy should be discontinued.

Hemorrhagic: Ticlid has been associated with a number of bleeding complications such as ecchymosis, epistaxis, hematuria, conjunctival hemorrhage, gastrointestinal bleeding, and postoperative bleeding.

Intracerebral bleeding was rare in clinical trials with Ticlid, and was no more than that seen with comparator agents (ASA, placebo).

Rash: Ticlopidine hydrochloride has been associated with a maculopapular or urticarial rash (often with pruritus). Rash usually occurs within 3 months of initiation of therapy, with a mean time to onset of 11 days. If drug is discontinued, recovery should occur within several days. Many rashes do not recur on drug rechallenge. There have been rare reports of more severe rashes.

Altered Laboratory Findings: Hematological: Neutropenia and rarely thrombocytopenia have been associated with Ticlid administration (see WARNINGS).

Liver: Ticlid therapy has been associated with elevations of alkaline phosphatase (See WARNINGS). Maximal changes occur within 1-4 months of therapy initiation. No further progressive increases are seen with continuous therapy. Occasionally patients developed deviations in bilirubin and SGOT.

Cholesterol: Chronic Ticlid therapy has been associated with increased serum cholesterol and triglycerides. Serum levels of HDL-C, LDL-C, VLDL-C, and triglycerides are increased 8-10% after 1-4 months of therapy. No further progressive elevations are seen with continuous therapy. The ratios of the lipoprotein subfractions are unchanged. The effect is not correlated with age, sex, alcohol use, or diabetes.

SYMPTOMS AND TREATMENT OF OVERDOSAGE One case of deliberate overdosage with Ticlid (ticlopidine hydrochloride) has been reported in a foreign postmarketing surveillance program. A 38 year old male took a single 6000 mg dose of Ticlid (equivalent to 24 standard 250 mg tablets). The only abnormalities reported were increased bleeding time and increased SGPT. No special therapy was instituted and the patient recovered without sequelae. Based on animal studies, overdosage may result in severe gastrointestinal intolerance.

In the case of excessive bleeding after injury or surgery, standard supportive measures should be carried out if indicated, including gastric lavage, platelet transfusion and use of corticosteroids.

DOSAGE AND ADMINISTRATION The recommended dose of Ticlid (ticlopidine hydrochloride) is 250 mg twice daily with food. Ticlid should be taken with meals to minimize gastrointestinal intolerance.

PHARMACEUTICAL INFORMATION

(i) Drug Substance

Description: Ticlopidine hydrochloride is a white crystalline solid. It is freely soluble in water and self buffers to a pH of 3.6. It also dissolves freely in methanol, is sparingly soluble in buffer solutions above pH 6.0, methylene chloride and ethanol, and is slightly soluble in acetone.

(ii) Composition: Ticlopidine hydrochloride tablets are provided, as white film coated tablets containing ticlopidine hydrochloride, citric acid, povidone, microcrystalline cellulose, corn starch, stearic acid powder, magnesium stearate and water. The coating suspension consists of hydroxypropyl methylcellulose, titanium dioxide and polyethylene glycol. The ink for printing contains D&C yellow #10 aluminum lake and FD&C blue #1 aluminum lake.

(iii) Stability and Storage Recommendations: Store at room temperature. Ticlid tablets should be dispensed in light resistant containers. Blister packs should not be exposed to light.

AVAILABILITY Ticlid 250 mg tablets are oval white film coated tablets printed using green ink with Ticlid above half an arrow on one side, "250" above half an arrow on the other side. The tablets are available in 2-week Patient Starter Packs of 28 tablets (2 blisters of 14 tablets). They are also available in boxes of 56 (4 x 14) tablets and 168 (12 x 14) tablets.


For the first 3 months of therapy, only request or dispense the 14 days supply of tablets (see PRECAUTIONS). Product Monograph available to Health Professionals on request.

REFERENCES 1. Adapted from Feinberg W. Antithrombotic therapy in stroke and transient ischemic attacks. *American Family Physician* 1989;40(Suppl):S35-9S. 2. Hass WK et al. Ticlopidine Aspirin Stroke Study (TASS). A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. *N Engl J Med* 1989;321:501-7. 3. Gent M et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. *The Lancet* 1989 Jun;1215-20. 4. Ticlopidine Aspirin Stroke Study (TASS). Data on file, Syntex Inc., Vol.52, Oct 1989. 5. Compendium of Pharmaceuticals and Specialties, 1992. 6. Ticlid product monograph.

SYNTEX® Syntex Inc. • Mississauga, Ont./Montréal (Qué.)
*Registered user of all ® trademarks

PAAB
CCPP
MEMBER
PMAC

Towards a rational treatment of epileptic seizures





GABA (γ -aminobutyric acid) is a major neurotransmitter which inhibits paroxysmal discharges in the brain. GABA is broken down by GABA transaminase (GABA-T). The resulting impairment of the GABA network may play a role in epilepsy.

Specific GABA-T inhibition increases whole brain and CSF GABA. Increasing the GABA pool has been shown to improve seizure control, in humans as well as in experimental models.

Research into specific GABA-T inhibition is helping develop rational medications which offer realistic hope to patients with uncontrolled seizures.

Pinpointing GABA-T for better seizure control



MARION MERRELL DOW

CANADA

(ix)

ACTIONS Parlodel (bromocriptine mesylate) is a dopaminomimetic ergot derivative with D₂ type dopamine receptor agonist activity, and has also D₁ dopamine receptor antagonist properties. The dopaminomimetic activity of bromocriptine in the striatum is considered responsible for the clinical benefits seen in selected patients with Parkinson's disease, when low doses of the drug are gradually added to levodopa therapy in patients on long-term treatment who develop late side effects of levodopa or no longer respond to the medication. Excessive dopaminomimetic drive may, however, provoke psychotic and other adverse reactions.

The extreme variability in G.I. tract absorption and the extensive and individually variable first-pass metabolism are responsible for the broad variability in plasma concentrations of bromocriptine and, in part, for the variability in dose response.

INDICATIONS[†] Parkinson's Disease: Parlodel (bromocriptine mesylate) has been found to be clinically useful as an adjunct to levodopa (usually with a decarboxylase inhibitor), in the symptomatic management of selected patients with Parkinson's disease who experience prominent dyskinesia or wearing off reactions on long-term levodopa therapy.

Patients on long-term treatment who are beginning to deteriorate on levodopa therapy may be controlled by reducing the dose of levodopa and adjusting the frequency and schedule of drug administration. Patients maintained on optimal dosages of levodopa who still experience prominent dyskinesia and/or end-of-dose failure may benefit from the concomitant use of Parlodel, by decreasing the occurrence and/or severity of these manifestations. Since rapid escalation of bromocriptine doses causes severe adverse reactions, it is recommended to combine a slow increase of Parlodel, usually with a concomitant, gradual and limited reduction of levodopa dosage. Continued efficacy of bromocriptine for more than two years has not been established and there is some evidence that its efficacy tends to wane. Evidence available indicates that there is no consistent benefit from bromocriptine in patients who have not responded previously to levodopa, and studies have shown significantly more adverse reactions in bromocriptine-treated patients than in patients treated with levodopa. Parlodel is not recommended in the treatment of newly diagnosed patients or as the sole medication in Parkinson's disease.

CONTRAINDICATIONS Other than sensitivity to ergot alkaloids, no absolute contraindications to treatment with Parlodel (bromocriptine mesylate) are known. For procedure during pregnancy see "Use in Pregnancy" under Precautions.

WARNINGS Long-term treatment (6-36 months) with Parlodel in doses of 20 to 100 mg/day has been associated with pulmonary infiltrates, pleural effusion and thickening of the pleura in a few patients. Where Parlodel was discontinued, these changes slowly reverted to normal.

PRECAUTIONS Parlodel (bromocriptine mesylate) may cause hypotension, primarily postural; periodic monitoring of the blood pressure, particularly during the first days of therapy, is advisable. In some patients dizziness (vertigo) may occur with Parlodel; patients should therefore be cautioned against activities requiring rapid and precise responses, such as driving an automobile or operating dangerous machinery, until their response has been determined.

Care should be exercised when administering Parlodel concomitantly with phenothiazines or antihypertensive agents. Due to drug interaction at the receptor site, dosage should be adjusted accordingly.

Alcohol should be avoided during treatment with Parlodel. In some patients, the concomitant use of Parlodel and alcohol has given rise to alcohol intolerance and an increase in the severity and incidence of Parlodel's possible adverse reactions.

Parlodel should always be taken with food. In cases

where severe adverse effects, such as nausea, vomiting, vertigo or headaches are severe or persisting, the therapeutic dosage of Parlodel should be reduced to half of one tablet daily (1.25 mg) and increased gradually to that recommended. The dopamine antagonist domperidone may be useful in the control of severe gastrointestinal side effects in parkinsonian patients receiving Parlodel (see Drug Interactions).

As with all medication, Parlodel should be kept safely out of the reach of children.

Use in Pregnancy: If the patient wishes to become pregnant, Parlodel (bromocriptine mesylate) should be stopped as soon as possible after conception is suspected. In this event immunological confirmation should be done immediately. When pregnancy is confirmed, Parlodel, like all other drugs, should be discontinued unless, in the opinion of the treating physician, the possible benefit to the patient outweighs the potential risk to the fetus.

In human studies with Parlodel (reviewed by Turkalj, I.), there were 1410 reported pregnancies, which yielded 1236 live and 5 stillborn infants from women who took Parlodel (bromocriptine mesylate) during early pregnancy. Among the 1241 infants, 43 cases (31 minor and 12 major) of congenital anomalies were reported. The incidence (3.46%) and type of congenital malformations and the incidence of spontaneous abortions (11.13%) in this group of pregnancies does not exceed that generally reported for such occurrences in the population at large.

Use in Parkinson's Disease: Use of Parlodel (bromocriptine mesylate), particularly in high doses, may be associated with mental confusion and mental disturbances. Since patients with Parkinson's disease may manifest varying degrees of dementia, caution should be exercised when treating such patients with Parlodel.

Parlodel administered alone or concomitantly with levodopa may cause visual or auditory hallucinations. These usually resolve with dosage reduction, but discontinuation of Parlodel may be required in some cases. Rarely, after high doses, hallucinations have persisted for several weeks following discontinuation of Parlodel. Caution should be exercised when administering Parlodel to patients with a history of myocardial infarction, particularly if they have a residual atrial, nodal or ventricular arrhythmia.

Symptomatic hypotension can occur and, therefore, caution should be exercised when administering Parlodel, particularly in patients receiving antihypertensive medication. Periodic evaluation of hepatic, hematopoietic, cardiovascular and renal function is recommended.

Drug Interactions: The concomitant use of erythromycin may increase bromocriptine plasma levels.

Domperidone, a dopamine antagonist, may cause increases in serum prolactin. In so doing, domperidone may antagonise the therapeutically relevant prolactin lowering effect of Parlodel. It is possible that the antitumorigenic effect of Parlodel in patients with prolactinomas may be partially blocked by domperidone administration.

ADVERSE REACTIONS The most frequently observed adverse reactions are nausea, vomiting, headache and gastrointestinal side effects such as abdominal pain, diarrhea and constipation. All these effects may be minimized or even prevented by giving small initial doses of bromocriptine and by taking it with food.

Postural hypotension which can, on rare occasions, lead to fainting and "shock-like" syndromes has been reported in sensitive patients. This is most likely to occur during the first few days of Parlodel treatment.

When bromocriptine is added to levodopa therapy, the incidence of adverse reactions may increase. The most common newly appearing adverse reactions in combination therapy were: nausea, abnormal involuntary movements,

hallucinations, confusion, "on-off" phenomenon, dizziness, drowsiness, faintness, fainting, vomiting, asthenia, abdominal discomfort, visual disturbance, ataxia, insomnia, depression, hypotension, shortness of breath, constipation and vertigo.

Less common adverse reactions include anorexia, anxiety, blepharospasm, dry mouth, dysphagia, edema of the feet and ankles, erythromelalgia, epileptiform seizures, fatigue, headache, lethargia, mottling of skin, nasal stuffiness, nervousness, nightmares, paresthesia, skin rash, urinary frequency, urinary incontinence, urinary retention and rarely signs or symptoms of ergotism such as tingling of fingers, cold feet, numbness, muscle cramps of feet and legs or exacerbation of Raynaud's syndrome.

Abnormalities in laboratory tests may include elevation of blood urea nitrogen, SGOT, SGPT, GGPT, CPK, alkaline phosphatase and uric acid, which are usually transient and not of clinical significance.

The occurrence of adverse reactions may be lessened by temporarily reducing dosage to one-half tablet two or three times daily.

SYMPTOMS AND TREATMENT OF OVERDOSE There have been several reports of acute overdosage with Parlodel (bromocriptine mesylate) in children and adults. No life threatening reactions have occurred. Symptoms reported included nausea, vomiting, dizziness, drowsiness, hypotension, sweating and hallucinations. Management is largely symptomatic; the cardiovascular system should be monitored. Metoclopramide can be used to antagonize the emesis and hallucinations in patients who have taken high doses.

DOSAGE AND ADMINISTRATION Parlodel (bromocriptine mesylate) should always be taken with food.

Although Parlodel (bromocriptine mesylate) has been found clinically useful in decreasing the severity and frequency of "on-off" fluctuations of late levodopa therapy, the decision to use bromocriptine as adjunctive treatment and the selection of dosage must be individualized in each case. A low dose is recommended. The initial dose of Parlodel is one half of a 2.5 mg tablet (1.25 mg) at bedtime with food to establish initial tolerance. Thereafter, the recommended dosage is 2.5 mg daily in two divided doses, with meals, (half a 2.5 mg tablet twice daily). The dosage may be increased very gradually, if necessary, by adding an additional 2.5 mg per day, once every 2 to 4 weeks, to be taken always in divided doses with meals. Increments should usually not exceed 2.5 mg. Clinical assessments are recommended at two week intervals or less during dosage titration, to ensure that the lowest effective dosage is not exceeded. The usual dosage range is from a few milligrams to 40 mg daily in two or three divided doses with meals. The median dose varies with the experience of individual investigators, but can be around 10 mg daily or higher. During initial titration it is recommended that the dosage of levodopa should be maintained, if possible. Subsequently, it might be desirable to combine a slow increase of bromocriptine with a concomitant, limited and gradual reduction of levodopa.

AVAILABILITY

TABLETS each containing 2.5 mg bromocriptine, as mesylate, available in bottles of 100.
CAPSULES each containing 5 mg bromocriptine, as mesylate, available in bottles of 100.

[†]For information on other approved indications, please consult the Parlodel Product Monograph, available to physicians and pharmacists on request.

*Registered trademark

PAAB

SANDOZ SANDOZ CANADA INC.
Dorval Quebec H9R 4P5

See ifc



**Be Part of a
Miracle!**

TRANSPLANTATION

A proven, effective treatment for end-stage organ disease.

Through transplants, hundreds of Canadians have a chance of a normal, productive life.

But many others don't get that chance. They die waiting for donated kidneys, hearts, lungs and livers.

Ask the families of brain-injured patients about organ donation. It doesn't conflict with the interests of these patients. It can give the families a chance to change pain and death into life and hope.


Remember TRANSPLANTS WORK

| | |
|-------------|----------------|
| MORE Ont. | 1-800-263-2833 |
| PORT B.C. | 1-800-663-6189 |
| HOPE Alb. | (403) 492-1970 |
| METRO Que. | (514) 876-6768 |
| OPEN Newf. | (709) 737-6600 |
| OPT-NB N.B. | (506) 648-6111 |
| HSC Man. | (204) 787-2379 |

OD-91-04-1639E

ROY T.
Kidney Transplant
June 26, 1989

Hope for better seizure control



GABA-T is an enzyme which breaks down GABA, a neurotransmitter that inhibits paroxysmal discharges in the brain.

Although a number of antiepileptic drugs act on the GABA system, none of the available anticonvulsants are known to exert specific GABA-T inhibition.

Research into GABA-T inhibition is helping develop specific medications which may help more epileptic patients achieve better seizure control.

Pinpointing GABA-T for better seizure control




MARION MERRELL DOW

CANADA
(xii)

NOW ELDEPRYL IS INDICATED FOR FIRST LINE THERAPY.

Now you can do more than deal with the disability of Parkinson's disease. You can delay it with Eldepryl first line. □ In newly diagnosed patients, Eldepryl can significantly retard the worsening of symptoms^{2,3} and delay the need for levodopa therapy.^{2,4,5} □ In fact, Eldepryl can delay the onset of disability and thereby prolong functional life by as much

as one year.^{1,4} □ As well, Eldepryl appears to have a remarkable safety profile. It has been generally well-tolerated with few side effects.^{4,6,7} □ So when you see patients with Parkinson's disease, prescribe



**HOLD BACK THE DISABILITY
OF PARKINSON'S DISEASE
FOR AN EXTRA YEAR.¹**






Eldepryl first line. It's their first line of defence against the progression of disability.

ELDEPRYL[®] FIRST LINE
selegiline hydrochloride

DELAYS THE PROGRESSION OF DISABILITY.


PAAB

Botulinum toxin information

| | |
|---|--|
|  | Physicians that are injecting |
|  | Reimbursement |
|  | Training seminars |
|  | Patient support groups |
|  | Safety/efficacy profile |

Call 1-800-44-BOTOX

This number provides you with the latest information on botulinum toxin and its use. Call today.



Botulinum Toxin Type A



On peut facilement reconnaître le jeune patient épileptique traité au Tegretol® CR.

Excellent contrôle des crises

☑ Tegretol® CR (carbamazépine à libération contrôlée) maîtrise les crises chez de nombreux patients, causant peu d'impact sur la fonction cognitive^{1,2}. Tegretol CR permet à de nombreux patients de penser clairement et de donner le meilleur d'eux-mêmes^{1,2}.

Taux sanguins uniformes

Tegretol CR cause moins de « hauts et de bas » dans les taux sanguins que le Tegretol conventionnel. Les effets secondaires sont ainsi réduits et le modèle de fonction cognitive est plus stable^{3,4}.

Posologie b.i.d. commode

Lorsque vous instituez ou remplacez un traitement, pensez au Tegretol CR. Il est présenté en comprimés à 200 mg et 400 mg facilement divisibles pour une plus grande souplesse d'administration et améliorer l'observance du patient.



TEGRETOL® CR.

*Aide les épileptiques à réaliser
leur plein potentiel.*

Geigy Dorval, Qué. H9S 1B1



G-93095F

Good news for patients taking oral contraceptives: Epival does not appear to be associated with O.C. failure.¹



Epival: For their epilepsy... and their lifestyles

A significant benefit for the newly diagnosed child with absence: Epival not only controls most patients with absence⁵, but is also effective against primary generalized seizures with tonic-clonic manifestations.^{4,8}



Proven efficacy in a broad range of primary generalized seizures^{4,5}


Little effect on learning and cognition³

Relatively few clinically substantiated drug interactions^{2,9}

Wide therapeutic range⁶ for easy titration

Most patients (85%) unable to tolerate other forms of valproic acid were able to take Epival⁷

A dual benefit for the elderly: Epival has relatively few clinically substantiated drug interactions^{2,9} and is rarely associated with ataxia or dyskinesias.³



Epival^{*}
divalproex sodium
A drug of choice in
primary generalized seizures

^{*}TM Abbott Laboratories, Limited

 PHARMACEUTICAL PRODUCTS DIVISION
ABBOTT LABORATORIES, LIMITED
MONTRÉAL, CANADA

PAAB MEMBER
PMAO